Transition Therapeutics Initiates Dosing in Phase II Diabetes Study
Posted on: Friday, 12 September 2008, 12:00 CDT
Canada-based biopharmaceutical company Transition Therapeutics has announced that the first patient has been dosed in a Phase II clinical study of gastrin analogue, TT-223, in patients with type 2 diabetes.
The study is a randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability and efficacy of daily TT-223 treatments for 12 weeks with a six-month follow-up.
Approximately 80 patients with type 2 diabetes are expected to be enrolled in the study and will receive a daily treatment of TT-223 in addition to their current regimen of oral glucose lowering agents (metformin or thiazolidinediones).
Transition and Eli Lilly and Company have previously entered into a licensing and collaboration agreement granting Lilly exclusive worldwide rights to develop and commercialize gastrin based therapies, including the lead compound TT-223.
Source: Datamonitor
Related Articles
- Transition Therapeutics Announces Initiation of a Phase Ib Clinical Study of TT-223 in combination with a GLP-1 analogue in Patients with Type 2 Diabetes
- Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients
- Transition Therapeutics Dose First Patient in Phase 2 Clinical Study of TT-223 in Type 2 Diabetes
- Ataxia, Autism, and the Cerebellum: a Clinical Study of 32 Individuals With Congenital Ataxia
- Leading Health Officials Raise Questions About Validity of Vitamin E Study, Call Findings 'Incomplete and Misleading,' Says NNFA
- A Pilot Study of the Effect of Inhaled Buffered Reduced Glutathione on the Clinical Status of Patients With Cystic Fibrosis*
- Risk Factors for the Metabolic Syndrome: The Coronary Artery Risk Development in Young Adults (CARDIA) Study, 1985-2001
- New Study Argues for Early Prostate Treatment
- Study Predicts Giant Wave of Extinctions
 |
 |
User Comments (0)
RSS Feeds